Stage-specific sensitivity to p53 restoration during lung cancer progression (original) (raw)
- Letter
- Published: 24 November 2010
- Kamena K. Kostova1,
- Monte M. Winslow1,
- Sarah E. Taylor1,
- Chris Cashman1,
- Charles A. Whittaker1,
- Francisco J. Sanchez-Rivera1,
- Rebecca Resnick1,
- Roderick Bronson2,
- Michael T. Hemann1 &
- …
- Tyler Jacks1
Nature volume 468, pages 572–575 (2010)Cite this article
- 11k Accesses
- 228 Citations
- 5 Altmetric
- Metrics details
Subjects
Abstract
Tumorigenesis is a multistep process that results from the sequential accumulation of mutations in key oncogene and tumour suppressor pathways. Personalized cancer therapy that is based on targeting these underlying genetic abnormalities presupposes that sustained inactivation of tumour suppressors and activation of oncogenes is essential in advanced cancers. Mutations in the p53 tumour-suppressor pathway are common in human cancer and significant efforts towards pharmaceutical reactivation of defective p53 pathways are underway1,2,3. Here we show that restoration of p53 in established murine lung tumours leads to significant but incomplete tumour cell loss specifically in malignant adenocarcinomas, but not in adenomas. We define amplification of MAPK signalling as a critical determinant of malignant progression and also a stimulator of Arf tumour-suppressor expression. The response to p53 restoration in this context is critically dependent on the expression of Arf. We propose that p53 not only limits malignant progression by suppressing the acquisition of alterations that lead to tumour progression, but also, in the context of p53 restoration, responds to increased oncogenic signalling to mediate tumour regression. Our observations also underscore that the p53 pathway is not engaged by low levels of oncogene activity that are sufficient for early stages of lung tumour development. These data suggest that restoration of pathways important in tumour progression, as opposed to initiation, may lead to incomplete tumour regression due to the stage-heterogeneity of tumour cell populations.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Similar content being viewed by others
Accession codes
Primary accessions
Gene Expression Omnibus
References
- Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000)
Article CAS Google Scholar - Selivanova, G. & Wiman, K. G. Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 26, 2243–2254 (2007)
Article CAS Google Scholar - Wang, W. & El-Deiry, W. S. Restoration of p53 to limit tumor growth. Curr. Opin. Oncol. 20, 90–96 (2008)
Article Google Scholar - Xue, W. et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656–660 (2007)
Article CAS Google Scholar - Martins, C. P., Brown-Swigart, L. & Evan, G. I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127, 1323–1334 (2006)
Article CAS Google Scholar - Ventura, A. et al. Restoration of p53 function leads to tumour regression in vivo . Nature 445, 661–665 (2007)
Article CAS Google Scholar - Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. & Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a . Cell 88, 593–602 (1997)
Article CAS Google Scholar - Palmero, I., Pantoja, C. & Serrano, M. p19ARF links the tumour suppressor p53 to Ras. Nature 395, 125–126 (1998)
Article ADS CAS Google Scholar - Lin, A. W. et al. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev. 12, 3008–3019 (1998)
Article CAS Google Scholar - Tuveson, D. A. et al. Endogenous oncogenic K-ras G12D stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5, 375–387 (2004)
Article CAS Google Scholar - Haigis, K. M. et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nature Genet. 40, 600–608 (2008)
Article CAS Google Scholar - Sarkisian, C. J. et al. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nature Cell Biol. 9, 493–505 (2007)
Article CAS Google Scholar - Jackson, E. L. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras . Genes Dev. 15, 3243–3248 (2001)
Article CAS Google Scholar - Johnson, L. et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410, 1111–1116 (2001)
Article ADS CAS Google Scholar - Quintanilla, M., Brown, K., Ramsden, M. & Balmain, A. Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 322, 78–80 (1986)
Article ADS CAS Google Scholar - Bremner, R. & Balmain, A. Genetic changes in skin tumor progression: correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7. Cell 61, 407–417 (1990)
Article CAS Google Scholar - Liu, M. L. et al. Amplification of Ki-ras and elevation of MAP kinase activity during mammary tumor progression in C3(1)/SV40 Tag transgenic mice. Oncogene 17, 2403–2411 (1998)
Article CAS Google Scholar - Junttila, M. R. et al. Selective activation of p53-mediated tumour suppression in high-grade tumours Nature doi:10.1038/nature09526. (this issue)
Article ADS CAS Google Scholar - Young, N. P. & Jacks, T. Tissue-specific p19Arf regulation dictates the response to oncogenic K-ras. Proc. Natl Acad. Sci. USA 107, 10184–10189 (2010)
Article ADS CAS Google Scholar - Lane, D. P. p53, guardian of the genome. Nature 358, 15–16 (1992)
Article ADS CAS Google Scholar - Meylan, E. et al. Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma. Nature 462, 104–107 (2009)
Article ADS CAS Google Scholar - Dickins, R. A. et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nature Genet. 37, 1289–1295 (2005)
Article CAS Google Scholar - Bolstad, B. M., Collin, F., Simpson, K. M., Irizarry, R. A. & Speed, T. P. Experimental design and low-level analysis of microarray data. Int. Rev. Neurobiol. 60, 25–58 (2004)
Article CAS Google Scholar - Bolstad, B. M., Irizarry, R. A., Gautier, L. & Wu, Z. in Bioinformatics and Computational Biology Solutions using R and Bioconductor (eds Gentleman, R., Carey, V., Huber, W., Irizarry, R. & Dudoit, S. ) Ch. 2, 13–32 (Springer, 2005)
Book Google Scholar - Smyth, G. K., Michaud, J. & Scott, H. S. Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics 21, 2067–2075 (2005)
Article CAS Google Scholar - Suzuki, R. & Shimodaira, H. Pvclust: an R package for assessing the uncertainty in hierarchical clustering. Bioinformatics 22, 1540–1542 (2006)
Article CAS Google Scholar
Acknowledgements
We would like to thank M. DuPage and C. Kim for critical reading of the manuscript. We are indebted to D. Crowley, E. Vasile and M. Griffin at the Koch Institute Core facilities (supported by Cancer Center Support (core) grant P30-CA14051 from the National Cancer Institute). We are grateful to M. Luo for microarray support. We thank M. Leversha at MSKCC for FISH. D.M.F. has been supported by the American Cancer Society (New England Area Fellow), and is a current Fellow of the Leukemia and Lymphoma Society. K.K.K. is supported by the John Reed Fund of the MIT undergraduate research program. M.M.W. was a Merck Fellow of the Damon Runyon Cancer Research Foundation and a Genentech postdoctoral fellow. T.J. is the David H. Koch Professor of Biology and a Daniel K. Ludwig Scholar. The Howard Hughes Medical Institute supported this work.
Author information
Authors and Affiliations
- Department of Biology, Koch Institute for Integrative Cancer Research, and Howard Hughes Medical Institute, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, 02139, Massachusetts, USA
David M. Feldser, Kamena K. Kostova, Monte M. Winslow, Sarah E. Taylor, Chris Cashman, Charles A. Whittaker, Francisco J. Sanchez-Rivera, Rebecca Resnick, Michael T. Hemann & Tyler Jacks - Tufts University, and Harvard Medical School, 77 Avenue Louis Pasteur, Boston, 02115, Massachusetts, USA
Roderick Bronson
Authors
- David M. Feldser
You can also search for this author inPubMed Google Scholar - Kamena K. Kostova
You can also search for this author inPubMed Google Scholar - Monte M. Winslow
You can also search for this author inPubMed Google Scholar - Sarah E. Taylor
You can also search for this author inPubMed Google Scholar - Chris Cashman
You can also search for this author inPubMed Google Scholar - Charles A. Whittaker
You can also search for this author inPubMed Google Scholar - Francisco J. Sanchez-Rivera
You can also search for this author inPubMed Google Scholar - Rebecca Resnick
You can also search for this author inPubMed Google Scholar - Roderick Bronson
You can also search for this author inPubMed Google Scholar - Michael T. Hemann
You can also search for this author inPubMed Google Scholar - Tyler Jacks
You can also search for this author inPubMed Google Scholar
Contributions
D.M.F. and T.J. conceived of the experiments and wrote the manuscript with comments from all authors; D.M.F., K.K.K, C.C., S.E.T. and R.R. performed the experiments and analysed the data; M.M.W. and F.J.S.-R. gave conceptual advice; R.B. performed histological evaluations; C.A.W. performed bioinformatics data analysis; and M.T.H. provided reagents and conceptual advice.
Corresponding author
Correspondence toTyler Jacks.
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Additional information
Gene expression data was deposited in Gene Expression Omnibus (GSE23875).
Supplementary information
PowerPoint slides
Rights and permissions
About this article
Cite this article
Feldser, D., Kostova, K., Winslow, M. et al. Stage-specific sensitivity to p53 restoration during lung cancer progression.Nature 468, 572–575 (2010). https://doi.org/10.1038/nature09535
- Received: 22 December 2009
- Accepted: 27 September 2010
- Published: 24 November 2010
- Issue Date: 25 November 2010
- DOI: https://doi.org/10.1038/nature09535
This article is cited by
Editorial Summary
Limits to antitumour effect of p53 restoration
Inactivation of the p53 tumour-suppressor pathway is a common feature of human cancers, prompting suggestions that restoring p53 function in established tumours might be an effective therapy. However, two papers in this week's Nature highlight a practical limitation of p53-directed cancer therapeutics. They show in a K-Ras-driven lung-cancer model that p53-mediated tumour suppression is engaged only at a late stage of tumour progression, when the K-Ras oncogenic signal reaches a threshold that is sufficient to activate the ARF-p53 pathway. This means that p53 re-expression fails to restrict the early stages of tumorigenesis, although it does induce regression of more aggressive tumours.